Budget Impact Analysis of Dabigatran Compared With Rivaroxaban in the Prevention of the Thromboembolic Risk in Patients With Non-Valvular Atrial Fibrillation. FE 2017, 18 (1). https://doi.org/10.7175/fe.v18i1.1327.